Increased BMP/SMAD Signaling by PD-MSCs Promotes Bone Formation in an Ovariectomized Mouse Model of Osteoporosis

Area of Science:

• Regenerative Medicine
• Bone Biology
• Immunology

Background:

• Mesenchymal stem cells (MSCs) offer therapeutic potential for degenerative diseases via paracrine signaling.
• Placenta-derived MSCs (PD-MSCs) possess advantageous properties like high proliferation and low immunogenicity for allogeneic use.

Purpose of the Study:

• To evaluate the therapeutic efficacy of PD-MSC transplantation in an estrogen-deficiency-induced osteoporosis mouse model.
• To investigate the impact of PD-MSCs on bone metabolism, inflammation, and key signaling pathways.

Main Methods:

• Establishment of an osteoporosis mouse model via estrogen deficiency.
• Comparison of three groups: normal control, non-transplanted osteoporosis, and PD-MSC-transplanted osteoporosis.
• Assessment of bone parameters (weight, volume, BMD, calcium), hormone levels, bone formation/resorption markers, inflammatory cytokines, and BMP/SMAD pathway activation.

Main Results:

• PD-MSC transplantation significantly improved femur weight, bone volume, bone mineral density, and calcium deposition.
• Elevated estrogen levels, upregulated bone formation markers, and downregulated bone resorption markers were observed.
• PD-MSCs modulated inflammation by reducing pro-inflammatory cytokines and increasing anti-inflammatory factors, alongside upregulation of the BMP/SMAD pathway.

Conclusions:

• PD-MSC transplantation effectively restores bone homeostasis in an osteoporosis model.
• The mechanism involves inhibiting osteoclast activity, promoting osteogenesis, and modulating inflammation.
• PD-MSCs represent a promising regenerative and anti-inflammatory therapeutic strategy for osteoporosis management.